6.17

5.65% 0.33

Atara Biotherapeutics Inc (ATRA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ATRA Giù? Forum Previsione

Precedente Chiudi:

$5.84

Aprire:

$5.84

Volume 24 ore:

23,959

Relative Volume:

0.14

Capitalizzazione di mercato:

$34.27M

Reddito:

$100.44M

Utile/perdita netta:

$-133.16M

Rapporto P/E:

-0.2395

EPS:

-25.76

Flusso di cassa netto:

$-94.85M

1 W Prestazione:

+16.42%

1M Prestazione:

-13.95%

6M Prestazione:

-34.22%

1 anno Prestazione:

-65.48%

Intervallo 1D:

$5.62

$6.18

Intervallo di 1 settimana:

$5.1559

$6.18

Portata 52W:

$5.005

$19.00

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Nome

Atara Biotherapeutics Inc

Settore

Healthcare (1151)

Industria

Biotechnology (660)

Telefono

805-623-4211

Indirizzo

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Dipendente

153

Cinguettio

@Atarabio

Prossima data di guadagno

2024-11-18

Ultimi documenti SEC

ATRA's Discussions on Twitter

Confronta ATRA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATRA Atara Biotherapeutics Inc	6.17	34.27M	100.44M	-133.16M	-94.85M	-25.76
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-11-09	Downgrade	Evercore ISI	Outperform → In-line
2023-11-09	Downgrade	H.C. Wainwright	Buy → Neutral
2023-11-09	Downgrade	Mizuho	Buy → Neutral
2022-07-20	Downgrade	Citigroup	Neutral → Sell
2022-07-13	Downgrade	JP Morgan	Overweight → Neutral
2022-07-13	Downgrade	Stifel	Buy → Hold
2022-05-10	Downgrade	Citigroup	Buy → Neutral
2021-05-13	Aggiornamento	JP Morgan	Neutral → Overweight
2020-12-09	Downgrade	Citigroup	Buy → Neutral
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-11-10	Reiterato	H.C. Wainwright	Buy
2020-06-30	Iniziato	Evercore ISI	Outperform
2020-06-15	Iniziato	H.C. Wainwright	Buy
2020-04-23	Aggiornamento	Citigroup	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Neutral
2019-09-27	Downgrade	Goldman	Neutral → Sell
2019-09-16	Downgrade	Jefferies	Buy → Hold
2019-06-04	Aggiornamento	Citigroup	Sell → Neutral
2019-05-30	Iniziato	ROTH Capital	Buy
2019-05-23	Iniziato	Stifel	Buy
2019-01-23	Iniziato	Mizuho	Buy
2018-04-10	Iniziato	JP Morgan	Overweight
2018-03-16	Iniziato	Guggenheim	Neutral
2018-03-05	Reiterato	Jefferies	Buy
2018-02-28	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Downgrade	Citigroup	Neutral → Sell
2018-01-03	Aggiornamento	Citigroup	Sell → Neutral
2017-10-06	Ripresa	Goldman	Neutral

Mostra tutto

Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie

Apr 08, 2025

Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech

Apr 08, 2025

Apr 07, 2025

Layoff Tracker: Spark Lays Off 298 Employees - BioSpace

Apr 07, 2025

Atara Biotherapeutics stock hits 52-week low at $5.3 - Investing.com

Apr 07, 2025

Apr 04, 2025

How the (ATRA) price action is used to our Advantage - news.stocktradersdaily.com

Apr 04, 2025

Atara Biotherapeutics IncOn March 31, Entered Amendment To Commercialization Agreement With Pierre FabreSEC Filing - marketscreener.com

Apr 04, 2025

Epstein-Barr Virus (EBV) Market Growth 2025: Trends, Consumer - openPR.com

Apr 04, 2025

Mar 26, 2025

Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - MSN

Mar 26, 2025

Mar 25, 2025

Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com

Mar 25, 2025

Mar 23, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 23, 2025

Mar 19, 2025

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 19, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Stock Crosses Below 50 Day Moving Average – Should You Sell? - Defense World

Mar 19, 2025

Mar 17, 2025

Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail

Mar 17, 2025

Mar 15, 2025

(ATRA) Investment Report - news.stocktradersdaily.com

Mar 15, 2025

Mar 13, 2025

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Mar 13, 2025

Mar 12, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World

Mar 12, 2025

Mar 11, 2025

Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks

Mar 11, 2025

Mar 10, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace

Mar 07, 2025